RT Journal
A1 Wu S, Ranpura V, Hapani S
T1 BEvacizumab and cancer treatment-related mortality—reply
JF JAMA
JO JAMA
YR 2011
FD June 8
VO 305
IS 22
SP 2291
OP 2293
DO 10.1001/jama.2011.760
UL http://dx.doi.org/10.1001/jama.2011.760
AB 
The goal of our study was to provide insight into the risk of FAEs related to chemotherapy associated with a biological agent, in this case bevacizumab. These events are most likely the result of serious adverse effects from the treatment, as shown in our study. We agree with Dr Punt and colleagues that many FAEs could be prevented by better adherence to treatment guidelines and adequate patient care. However, our study, being a meta-analysis, was limited in assessing these issues. The included studies did not contain any information regarding the assessment of the relationship between FAEs and treatment and major protocol violations and monitoring results.